MoneyWorks4Me

Bacil Pharma - Quaterly Results

15 Oct 2026 Evaluate
A slight decline in the revenue of Rs. 0.00 millions was seen for the September 2026 quarter as against Rs. 0.00 millions during year-ago period.The Net Loss for the quarter ended September 2026 is Rs. -0.09 millions as compared to Net Profit of Rs. 0.14 millions of corresponding quarter ended September 2025OP of the company witnessed a marginal growth to 0.33 millions from 0.19 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.85 0.00
Other Income 0.92 0.55 67.27 1.81 10.58 -82.89 12.35 0.00 0.00
PBIDT 0.33 0.19 73.68 0.99 9.13 -89.16 9.90 -0.58 -1806.90
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00
PBDT 0.33 0.19 73.68 0.99 9.13 -89.16 9.90 -0.59 -1777.97
Depreciation 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00
PBT 0.33 0.19 73.68 0.99 9.13 -89.16 9.90 -0.62 -1696.77
TAX 0.42 0.05 740.00 1.24 2.30 -46.09 -5.65 0.00 0.00
Deferred Tax 0.42 0.00 0.00 1.24 0.00 0.00 -5.65 0.00 0.00
PAT -0.09 0.14 -164.29 -0.25 6.83 -103.66 15.55 -0.62 -2608.06
Equity 139.70 139.70 0.00 139.70 139.70 0.00 139.70 139.70 0.00
PBIDTM(%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.92 0.00
Peers
Company Name CMP
Sun Pharma. Inds. 1753.95
Dr. Reddys Labs. 1239.00
Cipla 1329.90
Lupin 1928.00
Zydus Lifesciences 1135.00
View more..